EN DE
Watch Aktis Oncology, Inc. Common stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Aktis Oncology, Inc. (AKTS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Aktis Oncology, Inc. stock $11.43, price $17.45, that is 34.5% below the price, quality 20 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AO Aktis Oncology, Inc. logo Thin data Nov 10, 2026

Aktis Oncology, Inc.

AKTS · US
Weak valuation

Our calculation puts a fair price 34% below what the stock costs today.

Revenue last quarter +111% vs. a year ago.
Mixed Growth (revenue 5y +29.4 %/yr in USD)
Negative equity (buybacks among others)
Insiders sold $3.2M (6M)
Fair value $11.43 · Overvalued
Quality 20/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 12/100
Thin data
Estimate
Watch Aktis Oncology, Inc. Common stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$32.23 $14.59 Fair Value $11.43 Jan 2026 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

10‑month range $14.59 – $32.23 · fair‑value band $8.57 – $14.29 · the $17.45 price screens above the $11.43 fair value. As of Nov 10, 2026.

Follow Aktis Oncology, Inc. Common stock in your weekly email

Every Wednesday you see whether Aktis Oncology, Inc. Common stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.

Show moreShow less

The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.

It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020.

Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Stock analysis

Aktis Oncology, Inc. (AKTS) currently trades at $17.45, while our estimate is $11.43, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $8.57 (bear) to $14.29 (bull), the price of $17.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aktis Oncology, Inc. Common stock reported revenue of $6.5M in FY2025 versus $15.4M in FY2021, a compound −19.3%/yr. Reported net income was −$63.7M in FY2025.

Key figures

Market cap $965M Small · P/S ratio 93.2 · EPS (TTM) $−1.70 · Return on equity −29.5% · Return on assets (EBIT) −24.9% (5-year average) · Operating margin −854% · Revenue (TTM) $10.1M · Revenue growth (YoY) +111%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, AKTS screens richer than that median.

Fair Value

Bear $8.57 Fair Value $11.43 Bull $14.29
Price $17.45 · Downside -34.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 13
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $3.2M and none bought.

  • SaleAkos CzibereChief Medical Officer2× since Jul 8, 2026: 62,500 shares, avg. $26.36$1.6MSep 23, 2026
  • SaleKen HerrmannDirector2× since Jul 17, 2026: 7,921 shares, avg. $24.81$196,532Jul 20, 2026
  • SaleShulamit Ron-BiggerChief Operating Officer50,000 shares at $27.75$1.4MJul 8, 2026
  • BuyAnsbert Gadicke10% owner1,112,777 shares at $18.00$20.0MJan 12, 2026
  • BuyMPM ONCOLOGY INNOVATIONS FUND LP10% owner1,112,777 shares at $18.00$20.0MJan 12, 2026
  • BuyTodd FoleyDirector, 10% owner232,870 shares at $18.00$4.2MJan 12, 2026
  • BuyOleg NodelmanDirector2,222,222 shares at $18.00$40.0MJan 12, 2026
  • BuyHelen Susan KimDirector, 10% owner835,000 shares at $18.00$15.0MJan 12, 2026
  • BuyVIDA VENTURES II-A, LLC10% owner835,000 shares at $18.00$15.0MJan 12, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
Start year 2020 (pandemic). Over 10 years: +38.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,789.8% (2020) → −1,149.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AKTS screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Aktis Oncology, Inc. Common stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −34.5% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −24.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 111.4% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 95.96× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs AKTS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs AKTS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs AKTS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs AKTS
argenx SE ARGX $971.55 $908.40 −7% vs AKTS
CSL Limited CSL A$201.68 A$181.40 −10% vs AKTS
Moderna, Inc MRNA $250.83 $158.70 −37% vs AKTS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs AKTS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs AKTS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs AKTS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aktis Oncology, Inc. Common stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aktis Oncology, Inc. Common stock Fair Value". https://www.fairvalue-calculator.com/stock/AKTS

Frequently asked questions

Is Aktis Oncology, Inc. (AKTS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $11.43 versus a price of $17.45, about 34% lower (overvalued).
What is the fair value of AKTS?
Our estimate for Aktis Oncology, Inc. is $11.43 (as of Nov 10, 2026), built from audited fundamentals. The current price: $17.45.
What is the quality score of AKTS?
Aktis Oncology, Inc. has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aktis Oncology, Inc. (AKTS)?
Our calculated price target is the estimate of $11.43 (as of Nov 10, 2026). Cautious scenario $8.57, optimistic scenario $14.29. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Aktis Oncology, Inc. Common stock stock forecast for 2026?
Our estimate puts fair value at $11.43, about 34% lower versus a price of $17.45 (overvalued). Cautious scenario $8.57, optimistic scenario $14.29. The calculation is refreshed regularly with new filings.
What is the revenue of Aktis Oncology, Inc. (AKTS)?
Aktis Oncology, Inc. reported trailing-twelve-month revenue of about $10.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Aktis Oncology, Inc. (AKTS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aktis Oncology, Inc. it is $11.43 per share (as of Nov 10, 2026), against a price of $17.45.
Is Aktis Oncology, Inc. Common stock stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AKTS trades above its calculated fair value: price $17.45, fair value $11.43, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AKTS?
No. The price is what the market pays today ($17.45); the fair value is what the company's own numbers justify ($11.43). For Aktis Oncology, Inc. the two are $6.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aktis Oncology, Inc. Common stock worth?
The market values Aktis Oncology, Inc. at about $965M (market capitalisation, as of Nov 10, 2026). Per share that is $17.45; our models calculate a fair value of $11.43 per share.
What do the bullish and bearish scenarios say about AKTS?
Our models span a range for Aktis Oncology, Inc.: cautious scenario $8.57, base $11.43, optimistic $14.29 per share (as of Nov 10, 2026, price $17.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aktis Oncology, Inc. (AKTS)?
Balance-sheet figures for Aktis Oncology, Inc. (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
Which stocks are comparable to Aktis Oncology, Inc. Common stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aktis Oncology, Inc. Common stock stock attractive at the current price?
The data as of Nov 10, 2026: price $17.45, calculated fair value $11.43 (−34%), Quality Score 20/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Aktis Oncology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aktis Oncology, Inc. (AKTS)?
The closing price on Nov 10, 2026 was $17.45. Our estimate is $11.43, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aktis Oncology, Inc. Common stock right now?
The price sits above even our optimistic bull case ($14.29). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Aktis Oncology, Inc.

How large is the market capitalisation of Aktis Oncology, Inc. (AKTS)?
The market capitalisation of Aktis Oncology, Inc. is $965M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aktis Oncology, Inc. (AKTS)?
The price-to-sales ratio of Aktis Oncology, Inc. is 93.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aktis Oncology, Inc. (AKTS)?
Earnings per share at Aktis Oncology, Inc. are $−1.70. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Aktis Oncology, Inc. (AKTS)?
The return on equity (ROE) of Aktis Oncology, Inc. is −29.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aktis Oncology, Inc. (AKTS)?
On an EBIT basis the return on assets of Aktis Oncology, Inc. is −24.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aktis Oncology, Inc. (AKTS)?
The operating margin of Aktis Oncology, Inc. is −854% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aktis Oncology, Inc. (AKTS)?
Revenue at Aktis Oncology, Inc. is growing +111% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aktis Oncology, Inc. (AKTS) generate?
The free cash flow of Aktis Oncology, Inc. is −$73.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aktis Oncology, Inc. (AKTS) hold?
Aktis Oncology, Inc. holds more cash than debt, $26.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Aktis Oncology, Inc. Common stock in the live analysis

One click puts Aktis Oncology, Inc. Common stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.